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American Indians have a disproportionately high rate of
kidney disease likely due to a combination of environmental
and genetic factors. We performed a genome wide scan of
estimated glomerular filtration rate in 3665 participants of the
Strong Heart Family Study to localize genes influencing kidney
disease risk factors. The participants were men and women
from 13 American Indian tribes recruited from 3 centers
located in Arizona, the Dakotas and Oklahoma. Multipoint
variance component linkage analysis was performed for each
center and on the entire cohort after controlling for center
effects. Modeling strategies that incorporated age, gender and
interaction terms (model 1) and another that also controlled
for diabetes mellitus, systolic and diastolic blood pressure,
body mass index, low density and high density lipoproteins,
triglycerides and smoking status (model 2) were used.
Significant evidence for linkage in the Arizona group was
found on chromosome 12p12.2 at 39cM (nearest marker
D12S310) using model 1. Additional loci with very suggestive
evidence for linkage were detected at 1p36.31 for all groups
using both models and at 2q33.3 and 9q34.2 for the Dakotas
group each using model 1. No significant evidence for additive
interaction with diabetes, hypertension or obesity was noted.
This evidence for linkage of a quantitative trait locus
influencing estimated glomerular filtration rate to a region of
chromosome 12p in a large cohort of American Indians will be
worth studying in more detail in the future.
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Chronic kidney disease (CKD) is an important public health
problem affecting 8–11% of the US population.1,2 In addition
to the rising burden of end-stage renal disease, CKD is also a
strong risk factor for cardiovascular disease and death.
Worsening glomerular filtration rate (GFR) can result in up
to a threefold risk of cardiovascular events and a sixfold risk
of death.3 In the US, diabetes and hypertension are the most
common risk factors for CKD and end-stage renal disease.4
Even in the absence of diabetes, metabolic syndrome is
strongly associated with reduced GFR.5,6 Other identified risk
factors include glucose control,7,8 blood pressure control,9,10
body mass index,11 cholesterol levels,12,13 and smoking.14,15
American Indians are known to have higher rates of end-
stage renal disease than the general population, approxi-
mately twice than those of Caucasians.4,16,17 The vast
majority of kidney disease in American Indians is due to
diabetes, with rates of diabetic end-stage renal disease
approximately four times higher than in Caucasians, and
continuing to climb at a rapid pace in younger age groups.4
The prevalence of earlier stages of CKD is also high. A cohort
study of Navajo Indians found 3–6% of nondiabetics and
10–11% of diabetics had a creatinine clearance of less than
65 ml/min.18 Environmental risk factors for kidney disease
are highly prevalent in this population. The prevalence of
diabetes, hypertension, hypercholesterolemia, and obesity in
American Indians over 40 years of age has been reported to
range from 40 to 60, 25 to 35, 30 to 40, and 20 to 40%,
respectively.19–21 Smoking is highly prevalent with 26–38% of
American Indians being active smokers.19
Genetic predisposition to kidney disease is well ac-
cepted.17,22–24 Heritable factors have long been considered a
component of diabetic kidney disease,25,26 with multiple
genomic loci indicated in the development and progression
of diabetic nephropathy.23,24,27–31 Indeed, studies have
implicated the same genes or genomic regions in the
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predisposition or progression of any kidney disease, irre-
spective of the initial insult.32–36 Genetic factors may also play
a role in the variability of creatinine and GFR in populations
without kidney disease.34,37–39 The aim of the present study
was to identify genetic loci that are linked to the gene(s) that
influence phenotypic variation of GFR in a large population
of American Indian families.
RESULTS
A total of 3665 individuals were available for analysis from
the Strong Heart Family Study (SHFS; Arizona¼ 1235;
Dakotas¼ 1220; Oklahoma¼ 1210). Descriptive characteris-
tics of all SHFS participants are summarized in Table 1. The
average age±standard deviation of participants in each
center was approximately 39 years±15; 41 years±17, and 44
years±17 in Arizona, North and South Dakota, and
Oklahoma, respectively. Diabetes, hypertension, and obesity
were highly prevalent, especially, in the Arizona center.
Kidney disease was common, with albuminuria (urine
albumin:creatinine ratio (UACR) 430 mg/mg) present in
approximately 19% and depressed GFR (o60 ml/min per
1.73 m2) present in approximately 7% of individuals in all
centers (center-specific data not shown). There was wide
variation in albuminuria and estimated GFR with means of
106 mg/mg±598 and 99 ml/min per 1.73 m2±27 in all
centers, respectively. The distribution of CKD as defined by
the Kidney Disease Quality of Outcomes Initiative, among all
centers was: 11% stage 1, 28% stage 2, 4% stage 3, 0.5% stage
4, and 1% stage 5 CKD. Twenty percent (n¼ 722) of all
observations had an estimated glomerular filtration rate
(eGFR) 4120 ml/min per 1.73 m2. Five percent (n¼ 182) of
all observations had an eGFR 4120 ml/min per 1.73 m2 and
no proteinuria. For the analyses of those not on antihyper-
tensive medications, there were 738 participants deleted from
analysis and 486 of these had either diabetes and/or
proteinuria.
Genetic data were available for 460,000 relative pairs in
the full dataset and 418,000, 22,000, and 18,000 relative
pairs in Arizona, the Dakotas, and Oklahoma, respectively.
The number of participants with available genetic and
covariate data for the models 1 and 2 analyses were: 3605
and 3536 in all centers; 1215 and 1177 in Arizona; 1186 and
1174 in the Dakotas; and 1204 and 1185 in Oklahoma. Using
the fully adjusted models, the heritability estimates (standard
errors (s.e.)) of eGFR were consistent across centers:
approximately 0.33 (s.e.¼ 0.03), 0.33 (s.e.¼ 0.06), 0.34
(s.e.¼ 0.05), 0.33 (s.e.¼ 0.06) in the full sample, Arizona,
the Dakotas, and Oklahoma, respectively.
Analyses yielding logarithm of odds (LOD) scores X1.8
are displayed in Table 2. There was evidence for a quantitative
trait locus for GFR in the Arizona center using model 1
(LOD¼ 3.5) on chromosome 12 at 39 cM (nearest marker
D12S31), with a 16 cM 1-LOD unit support interval spanning
the regions 12p11.23–12p13.1.40 Loci with suggestive evi-
dence for linkage included 1p36.31 in all centers using both
models (LOD¼ 2.3, 2.0, respectively), 2q33.3 (LOD¼ 1.8)
and 9q34.2 (LOD¼ 2.4) using model 1 in the Dakotas.40
Data were very similar with the use of ranked inverse serum
creatinine as the outcome measure (results not shown).
When we excluded individuals on antihypertensive
medications from analysis, the LOD score on chromosome
12 increased to 4.6 in model 1 and 2.8 in model 2. LOD
scores on chromosome 1 remained similar in all centers,
however, analyses within Arizona now also yielded suggestive
LOD scores using both models (LOD¼ 2.5, 2.2, for models 1
and 2, respectively). Additionally, loci on chromosomes 2 and
9 were no longer significant and new loci were evident on
3q21.2 in Arizona using model 2 (LOD¼ 1.8) and 7p21.3 in
Table 1 | Descriptive statisticsa of phase IV Strong Heart Family Study participants (2001–2003)
Characteristics All Centers N=3665 Arizona N=1235 Dakotas N=1220 Oklahoma N=1210
Age (years) 40 (17) 37 (16) 39 (17) 44 (17)
Female gender, N (%) 2197 (60) 769 (62) 717 (59) 711 (59)
UACR (mg/mg) 97 (574) 152 (728) 76 (508) 64 (439)
Estimated GFRb, ml/min per 1.73 m2 100 (29) 112 (33) 96 (25) 93 (24)
Body mass index (kg/m2) 32 (8) 35 (9) 30 (7) 31 (7)
Systolic BP, (mm Hg) 123 (17) 121 (17) 120 (16) 127 (17)
Diastolic BP, (mm Hg) 76 (11) 77 (12) 75 (11) 77 (11)
LDL-C (mmol/l) 2.5 (0.8) 2.4 (0.7) 2.6 (0.8) 2.6 (0.8)
HDL-C (mmol/l) 1.3 (0.4) 1.3 (0.4) 1.3 (0.4) 1.4 (0.4)
Triglycerides, (mmol/l) 4.3 (4.4) 4.4 (3.5) 4.2 (5.2) 4.5 (4.4)
Hemoglobin A1C (%) 8.4 (2.1) 8.7 (2.2) 7.8 (1.9) 8.2 (2.0)
Hypertension, N (%) 1153 (31) 420 (34) 285 (23) 448 (37)
Antihypertensive treatment, N (%) 738 (20) 276 (22) 186 (15) 276 (23)
Diabetes, N (%) 830 (23) 410 (33) 172 (14) 248 (21)
Smoking, N (%)
Current 1230 (34) 311 (25) 518 (42) 401 (33)
Former 885 (24) 303 (25) 284 (23) 298 (25)
Never 1532 (42) 606 (49) 416 (34) 510 (42)
UACR, urine albumin to creatinine ratio; BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.
aMeans (±standard deviations) unless otherwise specified.
bCalculated using simplified MDRD.
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all centers and the Dakotas, using both models
(LODs¼ 1.9–2.3). Tests of additive interaction for gene-by-
diabetes, -hypertension, and -obesity were nonsignificant in
the full sample and every center at the 0.006 P-value
threshold level that accounts for multiple testing.
DISCUSSION
This study is only the third genome-wide scan of eGFR in a
general population not targeted for diabetes, hypertension or
end-stage renal disease34,41 and is one of the first to examine
gene-by-environment interactions in a linkage study of
estimated GFR. We found evidence of linkage to eGFR on
12p12.2 and suggestive evidence for linkage on 1p36.31,
2q33.3, and 9q34.2 (Figure 1). The locus on 12p12.2
replicates findings from a previous genome scan of diabetic
nephropathy in African Americans with a LOD score as high
as 2.9 in a subset of patients with late onset diabetes.27
Additionally, our finding of suggestive evidence for linkage to
2q33.3 replicates a study of GFR using cystatin-C in diabetics
(LOD¼ 4.1) and another of creatinine clearance in a general
population of Mexican Americans.41
The lack of gene-by-diabetes, -hypertension, and -obesity
interaction on GFR in our study population was somewhat
surprising. It is logical that there are genetic polymorphisms
that predispose to kidney disease only in the setting of
permissive environmental factors. Given that diabetes is the
Table 2 | Logarithm of odds scores suggestive of linkagea (LODX1.8) using two modeling strategies for multipoint quantitative
trait linkage analyses of ranked estimated glomerular filtration rate using the simplified modification of diet in renal disease
equation in phase IV participants of the Strong Heart Family Study (2001–2003)
Center Chromosome Location (cM) Chromosomal region Nearest marker Empirical LOD score (models 1, 2)b
All centers 1 12 1p36.31 D1S214 2.3, 2.0
Dakotas 2 205 2q33.3 D2S325 1.8, 0.5
Dakotas 9 150 9q34.2 D9S164 2.4, 1.7
Arizona 12 39 12p12.2 D12S310 3.5, 2.1
Model 2 was additionally adjusted for diabetic status, body mass index, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, triglycerides, and smoking status.
aLinkage significance criteria were as suggested by Rao and Gu.40
bModel 1 was adjusted for age, sex, age squared, and age–sex interactions.
0 50 100 150 200 250 300
0.0
0.5
1.0
1.5
2.0
2.5
3.0
LOD scores for chromosome 1
0 50 100 150 200 250 300
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 20 40 60 80 100 120 140 160 180
0.0
0.5
1.0
1.5
2.0
2.5
3.0
0 20 40 60 80 100 120 140 160 180
0
1
2
3
4
LOD scores for chromosome 2
LOD scores for chromosome 9 LOD scores for chromosome 12
gfr_all 
gfr_min_all 
gfr_az 
gfr_min_az 
gfr_da 
gfr_min_da 
gfr_ok 
gfr_min_ok 
gfr_all 
gfr_min_all 
gfr_az 
gfr_min_az 
gfr_da 
gfr_min_da 
gfr_ok 
gfr_min_ok 
gfr_all 
gfr_min_all 
gfr_az 
gfr_min_az 
gfr_da 
gfr_min_da 
gfr_ok 
gfr_min_ok 
gfr_all 
gfr_min_all 
gfr_az 
gfr_min_az 
gfr_da 
gfr_min_da 
gfr_ok 
gfr_min_ok 
LO
D 
sc
or
e
Chromosome position (cM)Chromosome position (cM)
LO
D 
sc
or
e
LO
D 
sc
or
e
Chromosome position (cM)
LO
D 
sc
or
e
Chromosome position (cM)
Figure 1 | Cumulative multipoint logarithm of odds (LOD) scores for ranked estimated glomerular filtration rate using the
simplified Modification of Diet in Renal Disease (MDRD) equation on chromosomes 1, 2, 9, and 12 in phase IV participants of the
Strong Heart Family Study (2001–2003). gfr_all: Model 2 in all centers; gfr_min_all: model 1 in all centers; gfr_az: model 2 in Arizona;
gfr_min_az: model 1 in Arizona; gfr_da: model 2 in Dakotas; gfr_min_da: model 1 in Dakotas; gfr_ok: model 2 in Oklahoma; gfr_min_ok:
model 1 in Oklahoma.
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most common cause of kidney disease in American
Indians, this seems a likely candidate to influence genetic
susceptibility. Interaction-specific linkage analysis is
underpowered and may alone explain the difference in
findings for diabetes interactions. Placha et al.41 found strong
evidence of gene-by-diabetes interaction on GFR using
cystatin-C in multiple extended families enriched for
diabetes. Cystatin-C was used to calculate GFR that may be
more accurate than creatinine-based methods for detecting
mild CKD specifically in American Indians and/or dia-
betics.42,43 The population used in the study by Placha et al.
was roughly 10-years older than the SHFS and also had a
lower mean body mass index. It is possible that misclassifica-
tion and the presence of glucose intolerance/metabolic
syndrome without overt diabetes may have contributed to
our finding of no interaction.
Our analysis isolated a quantitative trait locus for GFR
with a maximum LOD score of 3.5 at 12p12.2. In our
analysis, restricting the dataset to those not on antihyperten-
sive medications resulted in an increase of the LOD score to
4.6. Placha et al. also isolated significantly higher LOD scores
after inclusion of antihypertensive treatment as a covariate.41
The purpose of this subgroup analysis was twofold. First, it is
plausible that treatment with renin-angiotensin system
antagonists diminish the genetic propensity toward reduced
kidney function. We would have liked to have stratified by
treatment with renin-angiotensin system antagonists; how-
ever, this specific information was not available. Hence, we
used treatment with antihypertensives as a surrogate for
renin-angiotensin system antagonism. Second, as severe
hypertension may also act as either a confounder or effect
modifier on the propensity toward reduced kidney function,
we used treatment with antihypertensives as a marker of the
more severe hypertensive phenotype. The higher LOD score
on 12p obtained in the subanalysis of those not on
antihypertensive medications provides support for these
hypotheses.
Within the one-LOD drop support interval of our peak on
12p12.2 lies the gene protein-tyrosine phosphatase receptor
type-O. The protein, termed glomerular epithelial protein 1,
is primarily located on the apical surface of glomerular
podocytes and is present from early-on in development.44,45
Abnormalities in distribution are present in multiple human
primary glomerulopathies, including minimal change disease
and focal segmental glomerulosclerosis.46 Protein-tyrosine
phosphatase receptor type-O knockout mice are viable, but
podocytes have blunted, widened foot processes, and
decreased amounts of nephrin.47 Knockout mice have no
difference in urine albumin excretion or GFR as long as renal
reserve is intact. Uninephrectomized knockout mice, how-
ever, have a 25–50% lower GFR than their wild-type
counterparts, suggesting an increase in susceptibility to
decreased GFR in the presence of states of hyperfiltration.47
This is highly applicable to the Strong Heart population,
given the high prevalence of obesity, diabetes, and hyperten-
sion that also result in glomerular hyperfiltration.
There are several caveats to our reported findings. The
Modification of Diet in Renal Disease equation is less
accurate in those with an estimated GFR 460 ml/min per
1.73 m2 and the vast majority of the SHFS falls into this
category. Additionally, as the Modification of Diet in Renal
Disease equation was not developed in American Indians, the
estimates of GFR may have been biased. However, the
Modification of Diet in Renal Disease equation has been
validated in a study of Pima Indians using iothalamate as the
gold standard measurement.42 Although estimates of GFR
may be more accurate using cystatin-C than creatinine,
cystatin-C measures were not available. Analyses were not
repeated using the Cockroft–Gault equation because the high
prevalence of obesity in our study population would have
made it difficult to interpret results of creatinine clearance
based on weight.
The intraindividual variability of serum creatinine tends
to be high thus an average of repeated measures of serum
creatinine, had they been available, would have provided a
more optimal measurement of serum creatinine and
estimated GFR. Other factors that may affect levels of
measured serum creatinine in populations include hydration
status, concomitant medications, and random testing errors.
Estimates of GFR may also have been affected by obesity,
hypertension, and/or diabetes as a consequence of glomerular
hyperfiltration. The presence of a supranormal GFR is the
first stage of kidney disease for these conditions and hence
may misrepresent the true pathologic status when placed
within a continuous outcome variable paradigm. According
to this logic, 20% of our subjects fell into this category of
having a supranormal GFR, and excluding these participants
would not have been appropriate. Further complicating this
issue is that persons with a GFR 90–120 ml/min per 1.73 m2
may, in fact, possess more severe renal pathology than those
with a supranormal GFR, as they may have surpassed this
state and have declining renal function even though their
GFR is in the ‘normal range’. This is an issue inherent to renal
pathology that cannot be overcome or corrected for in the
analysis. From a physiologic standpoint, it would have been
interesting to have an ordinal outcome variable using the
Kidney Disease Quality of Outcomes Initiative staging system
for CKD; however, such an approach would be difficult to
implement, as linkage analysis requires either a two category
discrete or continuous outcome variable.
There was a significant decrease in the LOD score for the
locus on 12p12.2 in the fully adjusted model; however, this
may be explained by a loss of power alone. Analysis of the
fully adjusted model in Arizona incorporated 1177 indivi-
duals whereas the minimally adjusted model incorporated
1215 individuals. Although this difference would be minis-
cule in a general epidemiologic study, it is possible in a
linkage study that crucial individuals were dropped from the
analysis. The alternative possibility is that covariates
introduced in the maximum model are confounders in the
minimum model. We addressed this by running the analysis
using the covariates diabetes, hypertension, hypertension
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medication, obesity, body mass index, systolic, and diastolic
blood pressures as the outcome variable using the minimum
model over the 20 cM region on 12p. None of these analyses
were remotely suggestive of linkage. To address whether
albuminuria had confounded our analysis, we also ran the
analysis with UACR as the outcome variable and found no
evidence of linkage. In addition, there was no evidence of
genetic correlation between GFR and UACR. As we did not
incorporate hypertension, hypertensive medication or UACR
into the model, we also ran the analysis incorporating these
variables into the model and obtained the exact same results.
The validity of our findings is strengthened by two
indicators of robustness. First, the addition of hypertension,
hypertensive medication, and UACR did not alter the LOD
score isolated on 12p12.2. Second, this locus is a replication
of a previous genome scan of kidney disease and we
additionally replicated effect modification by antihyperten-
sive treatment. Lastly, within our 1-LOD drop support
interval is the candidate gene for glomerular epithelial
protein 1 that could logically influence eGFR in a population
prone to states of hyperfiltration. As very few genome-wide
linkage scans of eGFR have been published, and this region of
12p has been implicated in other populations, we should
direct future research into the refined mapping of the 12p12.2
region.
MATERIALS AND METHODS
Study population
The Strong Heart Study was begun in 1988 to investigate
cardiovascular disease and its risk factors in a geographically
diverse group of resident American Indian tribal members at
three study centers in Arizona, Oklahoma, and North and
South Dakota. The SHFS, a component of the Strong Heart
Study, was initiated in 1996 with the goal of localizing genes
that influence cardiovascular disease and its risk factors. The
data utilized for the current analysis were gathered during
phase IV of the SHFS, which occurred between 2001 and
2003. More than 3600 men and women aged 14–93 were
recruited from over 90 extended families originating from 13
separate American Indian tribes. The Arizona center is
primarily composed of Pima Indians, but there are also
representatives of the closely related Maricopa and Tohono
O’odham Indian tribes. The vast majority of participants in
the Dakotas center are Dakota/Lakota/Nakota. The Oklaho-
ma Center is represented by members of the Kiowa,
Comanche, Delaware, Apache, Caddo, Fort Sill Apache,
and Wichita tribes. All protocols were approved by the
Indian Health Service Institutional Review Board, by the
institutional review boards of the participating institutions
and by the 13 American Indian tribes participating in these
studies.
Phenotypes
Detailed descriptions of the Strong Heart Study and SHFS
study design and laboratory protocols have been published
previously.48,49 Blood pressure and body morphometrics
were measured during the physical exam. After 5 min of rest,
upper arm seated blood pressure was measured three times
by a trained technician using a mercury column sphygmo-
manometer (WA Baum Co.) and size-adjusted cuffs. The first
and fifth Korotkoff sounds were recorded. The average of the
last two measures was used for all analyses. Hypertension was
defined by a systolic blood pressureX140 mm Hg or diastolic
blood pressure X90 mm Hg or use of antihypertensive
drugs.10 Body mass index was calculated as weight (kg)/
height (m)2, and obesity was defined as a body mass index
X30 kg/m2. Type II diabetes was determined according to the
American Diabetes Association criteria.50
Fasting blood samples were assayed at MedStar Research
Institute, Washington D.C., using standard laboratory
methods as previously described.49 Triglycerides, total
cholesterol, and high-density lipoprotein cholesterol were
measured using enzymatic reagents and the Hitachi 717.
Low-density lipoprotein cholesterol was derived using the
Friedewald equation; it was directly measured in subjects
with triglyceride values of 4400 mg per 100 ml.51 Serum
creatinine was measured by the picric acid method.52 GFR
was estimated by the abbreviated Modification of Diet in
Renal Disease equation: GFR (ml/min per 1.73 m2)
¼ 186.3 (serum creatinine)1.154 (Age)0.203 (0.742 if
female) (1.210 if African American).53 This prediction
equation has been previously validated in an American
Indian population.42 GFR was calculated using the formula
for Caucasians. Information regarding smoking status was
obtained during a personal interview and was defined as
having ever had at least 100 cigarettes.
Genotypes
The SHFS genotyping procedures have been previously
described.54 In brief, DNA was isolated from fasting blood
samples using organic solvents, and then amplified in
separate PCR with primers specific for short-tandem repeat
markers using the ABI PRISM Linkage Mapping Set-MD10
version 2.5 (Applied Biosystems, Foster City, CA, USA). PCR
products were loaded into an ABI PRISM 377 DNA
sequencer for laser-based automated genotyping. Analyses
and assignment of the marker alleles were done using
computerized algorithms (Applied Biosystems).
Genetic distances were obtained using sex-averaged
chromosomal maps from the Marshfield Center for Medical
Genetics (http://research.marshfieldclinic.org/genetics) and
are reported in Haldane centiMorgans. Pedigree relationships
were verified using the pedigree relationship statistical tests
package, which employs likelihood-based inference statistics
for genome-wide identity-by-descent allele sharing.55 Men-
delian inconsistencies and spurious double recombinants
were detected using the SimWalk2 package.56 The overall
blanking rate for both types of errors was less than 1% of the
total number of genotypes for Arizona, Dakotas, and
Oklahoma. The cytogenetic locations of markers were
determined using the web resources of the University of
California Santa Cruz (UCSC) (http://www.genome/ucsc.edu)
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and the Marshfield Linkage maps (http://research.marshfieldclinic.
org/genetics/MarkerSearch/buildMap.asp).
Quantitative genetic analyses
Glomerular filtration rate was rank transformed to normalize
the distribution and attain a kurtosis of less than 1.0. SAS
(version 9.1) was used to calculate the residual variability
after covariate adjustment. To maximize the power to detect
genetic effects, we considered two different models of
covariate adjustment in each center and the full sample. In
model 1, adjustments were made for age, sex, age2, as well as
age-by-sex interactions. Model 2 incorporated additional
covariates supported by current literature as potential
confounders including: body mass index, systolic blood
pressure, diastolic blood pressure, triglyceride, high-density
lipoprotein cholesterol, low-density lipoprotein cholesterol,
diabetic status (yes versus no), and smoking status (current
and former versus never). Triglyceride levels were log
transformed and outliers from the distribution of systolic
blood pressure were set to 200 mm Hg (Winsorization) to
maintain normal distributions. The presence of ACEI/ARB
medications as well as hypertension severity could potentially
confound or modify the genetic influence over GFR.
Therefore, we additionally ran models 1 and 2 excluding
individuals on any antihypertensive medication (specific
medication use was unknown). All models were stratified by
center.
SOLAR (version 2.1.2) was used to perform multipoint
variance component linkage analysis of the residuals. Details
of this model have been described previously.57,58 The use of
the variance component approach requires an estimate of the
identity-by-descent matrix. We used the Loki package that
employs a Markov chain Monte Carlo stochastic procedure
to compute the identity-by-descent allele sharing at points
throughout the genome conditional on the genotype
information available at neighboring points.59
Interaction analyses
Genotype-by-diabetes, -hypertension, and -obesity interac-
tions on GFR were explored using a three-step strategy. We
initially tested for evidence of additive interaction by
accounting for the genetic covariance differences according
to diabetic, hypertension, or obesity status in relative pairs. In
these analyses, the likelihood of a model including genotype-
by-diabetes, -hypertension, or -obesity interactions is com-
pared to the likelihood of restricted models in which such
interactions are excluded. We tested for differential additive
genetic effects among diabetic versus nondiabetic, hyperten-
sive versus normotensive or obese versus nonobese partici-
pants (genetic correlation (rg) a1); for differences in the
magnitude of the genetic effects among diabetic versus
nondiabetic, hypertensive versus normotensive, and obese
versus nonobese participants (genetic variance (sg)a among
two groups); and for differences in residual environmental
interaction with diabetes, hypertension, or obesity status
(environmental variance (se) a among two groups).
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank the Strong Heart Family Study participants. Without their
participation, this project would not have been possible. In addition,
the cooperation of the Indian Health Service hospitals and clinics, and
the directors of the SHS clinics, and the many collaborators and staff
of the Strong Heart Study have made this project possible. This
research was funded by a cooperative agreement that includes
grants U01 HL65520, U01 HL41642, U01 HL41652, U01 HL41654, and
U01 HL65521 from the National Heart, Lung and Blood Institute.
Development of SOLAR and the methods implemented in it are
supported by US Public Health Service grant MH059490 from the
National Institutes of Health. The views expressed in this paper are
those of the authors and do not necessarily reflect those of the Indian
Health Service.
REFERENCES
1. Coresh J, Astor B, Greene T et al. Prevalence of chronic kidney disease and
decreased kidney function in the adult U.S. population: Third National
Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 1–12.
2. Culleton BF, Larson MG, Evans JC et al. Prevalence and correlates of
elevated serum creatinine levels: the Framingham Heart Study. Arch
Intern Med 1999; 159: 1785–1790.
3. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of
death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:
1296–1305.
4. U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-
Stage Renal Disease in the United States. National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney Diseases:
Bethesda, MD, 2006.
5. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for
chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;
16: 2134–2140.
6. Lucove J, Vupputuri S, Heiss G et al. Metabolic syndrome and chronic
kidney disease: the strong heart study. In: Department of Epidemiology.
University of North Carolina: Chapel Hill, 2006.
7. Writing Team for the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications Research
Group. Sustained effect of intensive treatment of type 1 diabetes mellitus
on development and progression of diabetic nephropathy: the
Epidemiology of Diabetes Interventions and Complications (EDIC) study.
JAMA 2003; 290: 2159–2167.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998; 352: 837–853.
9. Bakris GL, Weir MR, Shanifar S et al. Effects of blood pressure level on
progression of diabetic nephropathy: results from the RENAAL study.
Arch Intern Med 2003; 163: 1555–1565.
10. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint
national committee on prevention, detection, evaluation, and treatment
of high blood pressure. Hypertension 2003; 42: 1206–1252.
11. Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-
stage renal disease. Ann Intern Med 2006; 144: 21–28.
12. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the
progression of renal disease: a meta-analysis. Kidney Int 2001; 59:
260–269.
13. Fagot-Campagna A, Nelson RG, Knowler WC et al. Plasma lipoproteins
and the incidence of abnormal excretion of albumin in diabetic American
Indians: the Strong Heart Study. Diabetologia 1998; 41: 1002–1009.
14. Gambaro G, Verlato F, Budakovic A et al. Renal impairment in chronic
cigarette smokers. J Am Soc Nephrol 1998; 9: 562–567.
15. Pinto-Sietsma SJ, Mulder J, Janssen WM et al. Smoking is related to
albuminuria and abnormal renal function in nondiabetic persons. Ann
Intern Med 2000; 133: 585–591.
16. Stidley CA, Shah VO, Narva AS et al. A population-based, cross-sectional
survey of the Zuni Pueblo: a collaborative approach to an epidemic of
kidney disease. Am J Kidney Dis 2002; 39: 358–368.
17. Robbins DC, Knowler WC, Lee ET et al. Regional differences in
albuminuria among American Indians: an epidemic of renal disease.
Kidney Int 1996; 49: 557–563.
1190 Kidney International (2008) 74, 1185–1191
o r i g i n a l a r t i c l e AK Mottl et al.: Glomerular filtration rate in American Indians
18. Hoy W, Jim S, Warrington W et al. Urinary findings and renal function in
adult Navajo Indians and associations with type 2 diabetes. Am J Kidney
Dis 1996; 28: 339–349.
19. Welty TK, Rhoades DA, Yeh F et al. Changes in cardiovascular disease risk
factors among American Indians. The Strong Heart Study. Ann Epidemiol
2002; 12: 97–106.
20. Stidley CA, Shah VO, Scavini M et al. The Zuni kidney project: a
collaborative approach to an epidemic of kidney disease. J Am Soc
Nephrol 2003; 14: S139–S143.
21. Centers for Disease Control and Prevention (CDC). Diabetes prevalence
among American Indians and Alaska Natives and the overall population –
United States, 1994–2002. MMWR Morb Mortal Wkly Rep 2003; 52:
702–704.
22. Imperatore G, Knowler WC, Pettitt DJ et al. Segregation analysis of
diabetic nephropathy in Pima Indians. Diabetes 2000; 49: 1049–1056.
23. Imperatore G, Hanson RL, Pettitt DJ et al. Sib-pair linkage analysis for
susceptibility genes for microvascular complications among Pima Indians
with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998; 47:
821–830.
24. Vardarli I, Baier LJ, Hanson RL et al. Gene for susceptibility to diabetic
nephropathy in type 2 diabetes maps to 18q22.3-23. Kidney Int 2002; 62:
2176–2183.
25. Fogarty DG, Rich SS, Hanna L et al. Urinary albumin excretion in families
with type 2 diabetes is heritable and genetically correlated to blood
pressure. Kidney Int 2000; 57: 250–257.
26. Langefeld CD, Beck SR, Bowden DW et al. Heritability of GFR and
albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis
2004; 43: 796–800, 2004.
27. Bowden DW, Colicigno CJ, Langefeld CD et al. A genome scan for diabetic
nephropathy in African Americans. Kidney Int 2004; 66: 1517–1526.
28. Moczulski DK, Rogus JJ, Antonellis A et al. Major susceptibility locus for
nephropathy in type 1 diabetes on chromosome 3q: results of novel
discordant sib-pair analysis. Diabetes 1998; 47: 1164–1169.
29. Krolewski AS, Poznik GD, Placha G et al. A genome-wide linkage scan for
genes controlling variation in urinary albumin excretion in type II
diabetes. Kidney Int 2006; 69: 129–136.
30. Iyengar SK, Fox KA, Schachere M et al. Linkage analysis of candidate loci
for end-stage renal disease due to diabetic nephropathy. J Am Soc
Nephrol 2003; 14: S195–S201.
31. Sale MM, Freedman BI, Langefeld CD et al. A genome-wide scan for type
2 diabetes in African-American families reveals evidence for a locus on
chromosome 6q. Diabetes 2004; 53: 830–837.
32. Fox CS, Yang Q, Guo CY et al. Genome-wide linkage analysis to urinary
microalbuminuria in a community-based sample: the Framingham Heart
Study. Kidney Int 2005; 67: 70–74.
33. Freedman BI, Bowden DW, Rich SS et al. A genome scan for all-cause end-
stage renal disease in African Americans. Nephrol Dial Transplant 2005;
20: 712–718.
34. Fox CS, Yang Q, Cupples LA et al. Genomewide linkage analysis to serum
creatinine, GFR, and creatinine clearance in a community-based
population: the Framingham Heart Study. J Am Soc Nephrol 2004; 15:
2457–2461.
35. Freedman BI, Yu H, Spray BJ et al. Genetic linkage analysis of growth
factor loci and end-stage renal disease in African Americans. Kidney Int
1997; 51: 819–825.
36. Freedman BI, Rich SS, Yu H et al. Linkage heterogeneity of end-stage
renal disease on human chromosome 10. Kidney Int 2002; 62: 770–774.
37. Whitfield JB, Martin NG. The effects of inheritance on constituents of
plasma: a twin study on some biochemical variables. Ann Clin Biochem
1981; 21(Part 3): 176–183.
38. Bathum L, Fagnani C, Christiansen L et al. Heritability of biochemical
kidney markers and relation to survival in the elderly – results from a
Danish population-based twin study. Clin Chim Acta 2004; 349: 143–150.
39. Hunter DJ, Lange M, Snieder H et al. Genetic contribution to renal
function and electrolyte balance: a twin study. Clin Sci (Lond) 2002; 103:
259–265.
40. Rao DC, Gu C. False positives and false negatives in genome scans. Adv
Genet 2001; 42: 487–498.
41. Placha G, Poznik GD, Dunn J et al. A genome-wide linkage scan for genes
controlling variation in renal function estimated by serum cystatin C
levels in extended families with type 2 diabetes. Diabetes 2006; 55:
3358–3365.
42. Perkins BA, Nelson RG, Ostrander BE et al. Detection of renal function
decline in patients with diabetes and normal or elevated GFR by serial
measurements of serum cystatin C concentration: results of a 4-year
follow-up study. J Am Soc Nephrol 2005; 16: 1404–1412.
43. Macisaac RJ, Tsalamandris C, Thomas MC et al. Estimating glomerular
filtration rate in diabetes: a comparison of cystatin-C- and creatinine-
based methods. Diabetologia 2006; 49: 1686–1689.
44. Wiggins RC, Wiggins JE, Goyal M et al. Molecular cloning of cDNAs
encoding human GLEPP1, a membrane protein tyrosine phosphatase:
characterization of the GLEPP1 protein distribution in human kidney and
assignment of the GLEPP1 gene to human chromosome 12p12-p13.
Genomics 1995; 27: 174–181.
45. Wang R, St John PL, Kretzler M et al. Molecular cloning, expression, and
distribution of glomerular epithelial protein 1 in developing mouse
kidney. Kidney Int 2000; 57: 1847–1859.
46. Sharif K, Goyal M, Kershaw D et al. Podocyte phenotypes as defined
by expression and distribution of GLEPP1 in the developing glomerulus
and in nephrotic glomeruli from MCD, CNF, and FSGS. A dedifferentiation
hypothesis for the nephrotic syndrome. Exp Nephrol 1998; 6:
234–244.
47. Wharram BL, Goyal M, Gillespie PJ et al. Altered podocyte structure in
GLEPP1 (Ptpro)-deficient mice associated with hypertension and low
glomerular filtration rate. J Clin Invest 2000; 106: 1281–1290.
48. North KE, Howard BV, Welty TK et al. Genetic and environmental
contributions to cardiovascular disease risk in American Indians: the
strong heart family study. Am J Epidemiol 2003; 157: 303–314.
49. Lee ET, Welty TK, Fabsitz R et al. The Strong Heart Study. A study of
cardiovascular disease in American Indians: design and methods. Am J
Epidemiol 1990; 132: 1141–1155.
50. Report of the expert committee on the diagnosis and classification of
diabetes mellitus. Diabetes Care 1997; 20: 1183–1197.
51. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration
of low-density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
52. Chasson A, Grady H, Stanley M. Determination of creatinine by means
of automatic chemical analysis. Tech Bull Regist Med Tech 1957; 30:
207–212, 1957.
53. Levey A, Bosch J, Lewis J et al. A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction
equation. Modification of Diet in Renal Disease Study Group. Ann Inter
Med 1999; 130: 461–470.
54. North KE, Goring HH, Cole SA et al. Linkage analysis of LDL cholesterol in
American Indian populations: the Strong Heart Family Study. J Lipid Res
2006; 47: 59–66.
55. Sun L, Wilder K, McPeek MS. Enhanced pedigree error detection. Hum
Hered 2002; 54: 99–110.
56. Sobel E, Papp JC, Lange K. Detection and integration of genotyping
errors in statistical genetics. Am J Hum Genet 2002; 70: 496–508.
57. Almasy L, Blangero J. Multipoint quantitative-trait linkage analysis in
general pedigrees. Am J Hum Genet 1998; 62: 1198–1211.
58. Blangero J, Almasy L. Multipoint oligogenic linkage analysis of
quantitative traits. Genet Epidemiol 1997; 14: 959–964.
59. Heath SC. Markov chain Monte Carlo segregation and linkage analysis for
oligogenic models. Am J Hum Genet 1997; 61: 748–760.
Kidney International (2008) 74, 1185–1191 1191
AK Mottl et al.: Glomerular filtration rate in American Indians o r i g i n a l a r t i c l e
